account(Reuters) - Genetic Technologies Ltd said its lead cancer test BrevaGen has been cleared for sale in California, which it expects to be a large and significant market. The Nasdaq-listed shares of the company, which has operations in Australia and ...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Genetic Technologies gets nod to sell cancer test in California
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account